Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P508: Response of hepatitis B vaccination in patients with inflammatory bowel disease; prospective observational study in KoreaECCO '18 Vienna
Year: 2018
Authors:

J.Y. Chang*, S.-A. Jung, C.M. Moon, S.-E. Kim, H.-K. Jung, K.-N. Shim

Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea

P509: Long-term outcomes in biologic-treated perianal Crohn’s fistulaECCO '18 Vienna
Year: 2018
Authors:

S. Adegbola1*, W.Y. Mak2, K. Sahnan1, P. Tozer1,3, P. Bassett4, S. Hiles5, R. Phillips1, J. Warusavitarne1,3, O. Faiz1,3, A. Hart1,2

1St Mark’s Academic Institute, Robin Phillip’s Fistula Research Unit, London, UK, 2St Mark’s Hospital, Department of IBD, London, UK, 3St Mark’s Hospital, Department of Surgery, London, UK, 4St Mark’s Academic Institute, London, UK, 5LNWH ST MARKS HOSPITAL, Harrow, UK

P510: Hypergammaglobulinemia, hypoalbuminemia, and elevated CRP levels are predictors of a secondary loss of response to anti-TNFα therapy in IBDECCO '18 Vienna
Year: 2018
Authors:

F. Schoenefuss*, P. Hoffmann

Kliniken Essen Mitte, Gastroenterology, Essen, Germany

P511: Early prediction of steroid failure in acute severe ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

M.C. Choy1,2,3*, K. Boyd4, R. Burder4, A. Gorelik5, R. Nallas6, J. Horvath6, Q. Lam6, N. Crinis6, D. Van Langenberg7, M. Sparrow8, W. Connell3, K. Visvanathan3,9, P. De Cruz1,2

1Austin Health, Department of Gastroenterology, Melbourne, Australia, 2University of Melbourne, Austin Academic Centre, Melbourne, Australia, 3St. Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia, 4Austin Health, Gastroenterology, Melbourne, Australia, 5Australian Catholic University, Melbourne, Australia, 6Austin Health, Pathology, Melbourne, Australia, 7Eastern Health, Gastroenterology, Melbourne, Australia, 8Alfred Health, Gastroenterology, Melbourne, Australia, 9University of Melbourne, Medicine, Melbourne, Australia

P512: Herpes zoster infection in patients with ulcerative colitis receiving tofacitinibECCO '18 Vienna
Year: 2018
Authors:

K.L. Winthrop1, G.Y. Melmed2, S. Vermeire3*, M.D. Long4, G. Chan5, R.D. Pedersen5, N. Lawendy5, A.J. Thorpe5, C.I. Nduaka5, C. Su5

1Oregon Health and Science University, Portland, OR, USA, 2Cedars-Sinai Medical Center, Division of Gastroenterology, Department of Medicine, Los Angeles, CA, USA, 3University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 4University of North Carolina, Center for Gastrointestinal Biology and Disease, Chapel Hill, NC, USA, 5Pfizer Inc., Collegeville, PA, USA

P513: Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: Ten-year follow-up data from the Swiss IBD cohort studyECCO '18 Vienna
Year: 2018
Authors:

R. Frei1, N. Fournier2, J. Zeitz3, M. Scharl1, B. Morell1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann on behalf of the Swiss IBD Cohort Study Group7*

1University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Lausanne, IUMSP, Lausanne, Switzerland, 3Klinik Hirslanden, Department of Gastroenterology, Zurich, Switzerland, 4University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 5CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland, 6 Center of Gastroenterology and Hepatology, Zurich, Switzerland, 7University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

P514: Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small-molecule drugs in ulcerative colitis: A meta-analysisECCO '18 Vienna
Year: 2018
Authors:

F.S. Macaluso1*, M. Maida2, S. Renna1, M. Ventimiglia1, M. Cottone1, A. Orlando1

1Division of Internal Medicine, “'Villa Sofia-Cervello” Hospital, Palermo, Italy, 2Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, Italy

P515: Manipulating the microbiome in paediatric acute severe colitis with a cocktail of antibiotics: A pilot randomised controlled trialECCO '18 Vienna
Year: 2018
Authors:

D. Turner1*, H. Vlamakis2, D. Marcus1, M. Yassour2, J. Bishai2, B. Yerushalmi3, A. Griffiths4, M. Aloi5, L. Albenberg6, K.-L. Kolho7, G. Abutbul1, A. Assa8, R. Xavier2, A. Levine9

1Shaare Zedek Medical Center, Institute of Pediatric Gastroenterology, Jerusalem, Israel, 2The Broad Institute of MIT and Harvard, Cambridge, Center for Computational and Integrative Biology, Mass. General Hospital, Boston, USA, 3Soroka Medical Center, Beer Sheva, Israel, 4SickKids, Toronto, Canada, 5Sapienza University of Rome, Rome, Italy, 6CHOP, Philadelphia, USA, 7Children’s Hospital, Helsinki University, Helsinki, Finland, 8Schneider's Children Hospital, Petach Tiqva, Israel, 9Wolfson Medical Center, Holon, Israel

P516: Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trialsECCO '18 Vienna
Year: 2018
Authors:

J. Panés1*, B. Bressler2, J.-F. Colombel3, N. Lawendy4, E. Maller4, H. Zhang4, D.A. Woodworth4, G. Chan4, L. Salese4, C. Su4

1Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2University of British Columbia, Division of Gastroenterology, Department of Medicine, Vancouver, BC, Canada, 3Icahn School of Medicine at Mount Sinai Hospital, Division of Gastroenterology, New York, NY, USA, 4Pfizer Inc., Collegeville, PA, USA

P517: The effects and adherence of Asacol® comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: Prospective multicentre randomised studyECCO '18 Vienna
Year: 2018
Authors:

S.-K. Park1*, C.S. Eun2, G.S. Seo3, J. Lim4, T.O. Kim5, D.I. Park1

1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, South Korea, 2Hanyang University Guri Hospital, Guri, South Korea, 3Wonkwang University, Department of Internal Medicine, Jeonbuk, South Korea, 4Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 5Haeundae Paik Hospital, Inje University College of Medicine, Department of Internal Medicine and Gastroenterology, Busan, South Korea

P518: Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

C.-Y. Chao1,2*, S. Restellini1,3, C. Lemieux1, P. Germain1, A. Bitton1, P.L. Lakatos1,4, G. Wild1, E. Seidman1, T. Bessissow1, W. Afif1

1McGill University Health Centre, Division of Gastroenterology, Montréal, Canada, 2Princess Alexandra Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia, 3Geneva University Hospitals and University of Geneva, Department of Gastroenterology and Hepatology, Geneva, Switzerland, 4Semmelweis University, Department of Gastroenterology, Budapest, Hungary

P519: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months resultsECCO '18 Vienna
Year: 2018
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, J.M. Vázquez Morón2, H. Pallarés Manrique2, T. Valdes Delgado1, L. Castro Laria1, B. Maldonado Pérez1, R. Perea Amarillo1, V. Merino3, A. Caunedo Álvarez1, F. Argüelles-Arias1

1Virgen Macarena Hospital, Gastroenterology, Sevilla, Spain, 2Juan Ramón Jiménez Hospital, Gastroenterology, Huelva, Spain, 3Virgen Macarena Hospital, Pharmacy Unit, Sevilla, Spain

P520: Gastrointestinal ultrasonography in pregnant patients with IBD is useful in the identification of active intestinal inflammationECCO '18 Vienna
Year: 2018
Authors:

E. Flanagan1, E. Wright1, J. Begun2,3, R. Bryant4,5, D. Sathananthan4, S. Bell1*

1St Vincent's Hospital, Gastroenterology, Melbourne, Australia, 2Mater Hospital, Gastroenterology, Brisbane, Australia, 3Mater Research Institute, Brisbane, Australia, 4Queen Elizabeth Hospital, Gastroenterology, Adelaide, Australia, 5University of Adelaide, Adelaide, Australia

P521: Evaluation of adalimumab effectiveness in paediatric patients with ulcerative colitis in clinical practiceECCO '18 Vienna
Year: 2018
Authors:

S. Steiner1*, C. Liu2, E. King2, E. Israel3, B. Pasternak4, M. Schaefer5, S. Chen2, J. Pratt2, A. Lazar6, M. Bereswill6, A. Robinson7, R. Colletti8, ImproveCareNow Network9

1Indiana University School of Medicine, Indianapolis, USA, 2Cincinnati Children's Hospital Medical Center, Cincinnati, USA, 3Massachusetts General Hospital for Children, Boston, USA, 4Phoenix Children's Hospital, Phoenix, USA, 5Penn State Children's Hospital, Hershey, USA, 6Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 7AbbVie, North Chicago, USA, 8University of Vermont Children’s Hospital, Burlington, USA, 9ImproveCareNow, Burlington, USA

P522: Soluble sMadCAM1 and retinoic acid are potential tools for therapeutic drug monitoring in inflammatory bowel disease s under vedolizumab: A proof of conceptECCO '18 Vienna
Year: 2018
Authors:

X. Roblin1*, N. Williet1, G. Boschetti2, B. Flourie2, E. Del Tedesco3, L. Peyrin Biroulet4, J.m. Phelip3, S. Nancey2, S. Paul5

1CHU Saint Etienne, Saint Etienne, France, 2University of Lyon, Lyon, France, 3University Hospital, Gastroenterology, Saint Etienne, France, 4CHU de Nancy, Department of Gastroenterology, Vandoeuvre-les-Nancy, France, 5University of Saint Etienne, Immunology, Saint Etienne, France

P523: New guidance on therapeutic drug monitoring; potential clinical and cost implicationECCO '18 Vienna
Year: 2018
Authors:

R. Felwick*, H. Johnson, H. Dewhurst, E. Cadogan, C. Hovell, S. Weaver, S. McLaughlin

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, UK

P524: Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: A prospective evaluationECCO '18 Vienna
Year: 2018
Authors:

I. Bruna-Barranco1, P. Alarcon2, A. Lué3,4, C. Gargallo3,4, E. Alfambra4, M. Gimeno5, F. Gomollon2,3,4,6*

1Hospital Universitario Miguel Servet, Zaragoza, Spain, 2Universidad de Zaragoza, Zaragoza, Spain, 3Fundación IIS Aragon, Zaragoza, Spain, 4Hospital Clinico Universitario Lozano Blesa, Gastroenterology Department, Zaragoza, Spain, 5Hospital Clinico Universitario Lozano Blesa, Pharmacy Department, Zaragoza, Spain, 6CIBERehd, Barcelona, Spain

P525: Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centreECCO '18 Vienna
Year: 2018
Authors:

K. Null1*, H.L. Chang2, T. Lissoos1, M. Luo1, B. Cohen2, B.E. Sands2, A. Atreja2

1Takeda Pharmaceuticals USA, Inc., Deerfield, USA, 2Icahn School of Medicine at Mount Sinai, New York, USA

P526: Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort studyECCO '18 Vienna
Year: 2018
Authors:

K. Novak1*, J. Halasz1, C. Lu1, G. Kaplan1,2, C. Seow1, D. Tanyingoh2, S. Devlin1, R. Panaccione1, S. Wilson3

1University of Calgary, Gastroenterology, Calgary, Canada, 2University of Calgary, Community Health Sciences, Calgary, Canada, 3University of Calgary, Foothills Medical Centre, Diagnostic Imaging, Calgary, Canada

P527: Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patientsECCO '18 Vienna
Year: 2018
Authors:

B. Verstockt1,2*, G. Moors1, S. Bian3, T. Van Stappen3, S. Tops3, V. Ballet1, G. Van Assche1,2, S. Vermeire1,2, A. Gils3, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium